Dravet Syndrome is also known as Severe Myoclonic Epilepsy of Infancy (SMEI), a rare and catastrophic treatment-resistant form of childhood epilepsy. Following confirmation from FDA, the company intends
As part of the deal, Bayer will acquire Merck’s existing OTC business, including the global trademark and prescription rights for Claritin and Afrin. Merck has also entered into
CMC Biologics global chief operations officer Gustavo Mahler said the company looks forward to working with MacroGenics to further develop and advance this immuno-oncology program. "This contract highlights
The new inhibitors will be developed against an Eternygen target to treat metabolic diseases using Evotec’s technology platform and broad expertise in drug discovery and pre-clinical development. Currently,
Under the deal, each company has made a $1m investment in CET, which is majority owned by Cumberland and partners with academic research centers to develop promising biopharmaceutical
The sNDA application was granted Priority Review designation with a stated FDA Prescription Drug User Fee Act (PDUFA) review date of 18 September 2014. Currently, XTANDI is approved
Triglycerides are a type of fat found in blood and an important energy source for the body. According to the company, EPANOVA is the first FDA approved prescription
With this approval, physicians who treat adults with chronic or accelerated phase CML who are no longer responding to, or who could not tolerate, two or more tyrosine
The project is aimed at exploring a genetic cause in hereditary forms of the disease as a platform for developing disease-modifying treatment that would slow or stop the
Dr. Huib Ovaa is principal investigator of Chemical Biology Laboratories at NKI and a member of FORMA’s deubiquitinase (DUB) investigator network. As part of the deal, FORMA and
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.